BCL2L1 and melanoma: In melanoma cells, enhanced caspase-3 activation and mitochondrial activation have been reported in response to combinations of S63845 or TW-37 (targeting Mcl-1, Bcl-xL and Bcl-2) with BRAF inhibitors (vemurafenib or encorafenib) [58,59].